IDEAYA Biosciences (NASDAQ:IDYA) expands its clinical trial collaboration and supply agreement with Pfizer (NYSE:PFE) with a new study evaluating the combination of IDE196, a protein kinase inhibitor, and crizotinib, a cMET inhibitor, in patients with GNAQ or GNA11 mutation-positive solid tumors, including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.
IDEAYA's clinical development plan in MUM for IDE196 is based on combination therapies, including with binimetinib, a MEK inhibitor, and crizotinib. It announced First-Patient-In (FPI) for the IDE196 and binimetinib clinical combination in June 2020 and is targeting FPI for the crizotinib clinical trial combination in late 2020 to early 2021. It is also evaluating IDE196 as monotherapy in an ongoing GNAQ/11 non-MUM basket trial in additional solid tumor types, including in skin melanoma, where the company announced Phase 2 expansion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.